Rare and severe adverse reaction diabetic ketoacidosis induced by bevacizumab：one case report
- VernacularTitle:贝伐珠单抗致罕见严重不良反应糖尿病酮症酸中毒的个案分析
- Author:
Baoping XU
1
;
Huaiwen PENG
1
;
Huaibin YU
1
;
Nanxun SHEN
2
;
Xiaotao WANG
3
Author Information
1. Dept. of ICU，the Fourth Clinical Medical College of Anhui University of Chinese Medicine （Lu’an Hospital of Traditional Chinese Medicine），Anhui Lu’an 237000，China
2. Dept. of Pharmacy，the Fourth Clinical Medical College of Anhui University of Chinese Medicine （Lu’an Hospital of Traditional Chinese Medicine），Anhui Lu’an 237000，China
3. Dept. of Traditional Chinese Medicine，Ehu Branch of Xishan People’s Hospital of Wuxi City，Jiangsu Wuxi 214116，China
- Publication Type:Journal Article
- Keywords:
bevacizumab;
diabetic ketoacidosis;
rare adverse reaction;
severe adverse reaction;
pancreatic function
- From:
China Pharmacy
2024;35(7):877-880
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for the safe use of bevacizumab in cancer patients. METHODS The diagnosis and treatment of a 65-year-old female lung adenocarcinoma patient with diabetic ketoacidosis （DKA） induced by bevacizumab was retrospectively analyzed， and the possible mechanisms and causes were analyzed based on literature review. RESULTS & CONCLUSIONS The diagnosis and treatment process of patients were analyzed， and DKA caused by other drugs and disease factors were excluded. DKA was considered to be caused by the use of bevacizumab according to Naranjo’s ADR evaluation scale； the acidosis of the patient improved rapidly after one hemodialysis treatment. DKA caused by bevacizumab is rare in clinic， clinicians should be aware that bevacizumab may affect pancreatic function and induce DKA， and early detection and treatment should be achieved to improve the prognosis.
